Petra Acquisition filed an S-4 registration statement on its proposed merger with Revelation Biosciences, a deal that values the combined enterprise at $128 million.
A shareholder vote date was not included in the preliminary proxy. Petra two weeks ago said it would ask shareholders for an extension on sealing the deal by Dec. 13 from the looming Oct. 13 deadline.
Terms call for Revelation to receive the $73 million of cash in Petra’s trust. Revelation’s existing stockholders will own approximately 54% of the fully diluted shares of common stock of the combined company if the deal is approved.
Revelation is a clinical stage life sciences company focused on the development of immunologic‑based therapies for the prevention and treatment of disease, particularly respiratory viruses. Read more.
